MLX interacting protein (MondoA) (MondoA)

MondoA (MLX interacting protein) is a basic helix-loop-helix leucine zipper (bHLH-LZ) transcription factor that serves as a primary nutrient sensor, particularly for glucose and its metabolites like glucose-6-phosphate (G6P) (Frontiers in Endocrinology, 2023; JCI Insight, 2019). It forms a heterodimer with Max-like protein X (MLX) and translocates from the outer mitochondrial membrane to the nucleus in response to high glucose levels to regulate the expression of genes involved in energy homeostasis (NIH/RefSeq, 2014; Diabetes, 2018). Key transcriptional targets include thioredoxin-interacting protein (TXNIP) and arrestin domain-containing 4 (ARRDC4), which act as negative regulators of glucose uptake, creating a feedback loop to prevent cellular energy overload (Frontiers in Endocrinology, 2023; JCI Insight, 2019). In conditions of chronic nutrient excess, persistent MondoA activity contributes to insulin resistance, obesity, and type 2 diabetes by promoting lipid accumulation in skeletal muscle and suppressing insulin signaling (JCI Insight, 2019; Pharmaceutical Journal, 2021). Beyond metabolic diseases, MondoA is implicated in various cancers, such as triple-negative breast cancer and B-cell lymphomas, where it facilitates metabolic reprogramming to support tumor growth and survival (Cancer Research, 2015; NIH, 2026). Therapeutic strategies targeting MondoA, including small molecule inhibitors like SBI-477, aim to improve insulin sensitivity and reduce lipotoxicity by deactivating its transcriptional program (MedChemExpress; Frontiers in Endocrinology, 2023).

Other names

MLXIPbHLHe36MIRKIAA0867Class E basic helix-loop-helix protein 36Transcriptional activator MondoA

Inhibition of MondoA-MLX transcriptional activity to reduce the expression of negative regulators of glucose uptake (TXNIP and ARRDC4) and genes involved in lipid synthesis, thereby improving insulin sensitivity and metabolic flexibility.